Clinical Trials Logo

Tumor Markers, Biological clinical trials

View clinical trials related to Tumor Markers, Biological.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00748358 Completed - Prostatic Neoplasms Clinical Trials

An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer

PROSUT
Start date: March 2008
Phase: Phase 2
Study type: Interventional

as second-line treatment in metastatic prostate cancer, the present study will investigate the efficacy of sunitinib (SUTENT) given orally at a dose of 37.5 mg continuously, for 6 cycles of 6 consecutive weeks .Patients who are still responders after 6 cycles will be treated until disease progression, pain progression, unacceptable toxicity or death due to any cause. Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability. Follow-up for up to 1 year from the last dose of sunitinib.

NCT ID: NCT00495924 Completed - Clinical trials for Pancreatic Neoplasms

Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma

Start date: October 2006
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether early recurrence after curative resection of ductal pancreatic adenocarcinoma can be explained by either dissemination of cancer cells during intraoperative tumour manipulation, post-operative systemic immune suppression, alteration of biological properties of circulating cancer cells or a combination of these.